BioSpace News Archive

Castle Biosciences, Inc. today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023.

Precision BioSciences, Inc. today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).

Zevra Therapeutics, Inc. today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed as a treatment for Niemann-Pick disease type C (NPC), is being featured in two poster presentations during the 19th Annual WORLDSymposium™ 2023, the annual research conference dedicated to lysosomal diseases being held February 22-26, 2023 in Orlando, Florida, USA.

Windtree Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,583,540, providing expanded patent coverage for istaroxime administration.

Regeneron Pharmaceuticals, Inc. announced the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Libtayo® in combination with platinum-based chemotherapy.

Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) today announced that on February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease.

The International Federation of Pharmaceutical Wholesalers, in partnership with member companies including global healthcare company AmerisourceBergen and IQVIA, a leading provider of advanced analytics and technology solutions, launched an ESG framework and toolkit to serve as a resource for the industry.

SELLAS Life Sciences Group, Inc. announced the pricing of its previously announced underwritten public offering of 7,220,217 shares of its common stock and accompanying warrants to purchase up to 7,220,217 shares of common stock at a combined public offering price of $2.77 per share and accompanying warrant.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced its participation in the upcoming investor conferences.

IRADIMED CORPORATION issued an Urgent Medical Device Correction Letter to notify affected customers of a potential issue with some 1057 Syringe Adapter Sets related to the syringe venting function during use which can lead to reduced flow with the MRidium infusion pump resulting in subsequent inlet occlusion and alarm indication.